Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

Table 2 Study calendar

Procedure	Pre Study	Pre-RT (up to 4 months prior)	Baseline Pre-SBRT Day 1	On Tx SBRT 5 fx	POST TREATMENT VISITS (+/− 4 weeks)*
					1 month (+/− 4 wks)	3 month (+/− 4 wks)	6 month (+/− 4 wks)	9 month (+/− 4 wks)	12 month (+/− 4 wks)	18 month (+/− 4 wks)	24 month (+/− 4 wks)	Q 6 month × 4 yrs		EOS Or Early Term Visit
					1 month (+/− 4 wks)	3 month (+/− 4 wks)	6 month (+/− 4 wks)	9 month (+/− 4 wks)	12 month (+/− 4 wks)	18 month (+/− 4 wks)	24 month (+/− 4 wks)	30 M 36 M 42 M	48 M 54 M 60 M (+/− 4 wks)	EOS Or Early Term Visit
Informed Consent	x
Demographics	x
Medical History	x
SOC Physical Exam	x													x
Toxicity assessments / Quality of Life Questionnaires		x**	x**		x	x	x	x	x	x	x	x		x
SOC Non-Contrast Pelvic CT scan^***		x
SOC MRI of the Prostate or Pelvis		x
SOC PSA Draw****		x				x	x	x	x	x	x	x		x
Translational saliva collection◦			x
Record Radiation Therapy - 5 fractions				x

* Follow-up visits can be conducted over the telephone, with remote collection of QOL information
**Toxicity and QOL assessment required either at pre-RT OR pre-SBRT, but not at both time points
*** For patients with PSA < 1.0 ng/mL, the treatment planning CT can substitute for a diagnostic CT scan (in this case, the CT simulation should be within 1 month of radiotherapy initiation)
**** These SOC blood samples can be drawn remotely, in the event that the patient is following up outside the UCLA system. In these cases, the lab reports should be provided to the study investigators
◦ Whenever feasible, but may be waived
EOS, end of study; SOC, standard of care

ISSN: 1471-2407